RBM15B

Across TCGA pan-cancer cohorts, RBM15B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBM15B data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RBM15B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RBM15B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where RBM15B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.943	0.744	.006	35	view →
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	9	view →
HNSC	OS	Median	All	0.636	0.804	.019	7	view →
LSCC	DFS	Tertile	All	1.000	0.914	.015	6	view →
UCEC	OS	Tertile	All	0.867	1.000	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBM15B–CCRCC (OS)

Open the CCRCC breakdown →